États-Unis - anglais - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae ar

États-Unis - anglais - NLM (National Library of Medicine)

wilshire pharmaceuticals - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes; streptococcus pneumoniae; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations o

États-Unis - anglais - NLM (National Library of Medicine)

wilshire pharmaceuticals - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrati

Malaisie - anglais - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dynapharm (m) sdn bhd - erythromycin stearate -

États-Unis - anglais - NLM (National Library of Medicine)

stat rx usa - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release capsules and other antibacterial drugs, erythromycin delayed-release capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the er

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - erythromycin - gastro-resistant tablet - 250mg

Canada - anglais - Health Canada

pro doc limitee - erythromycin stearate - tablet - 250mg - erythromycin stearate 250mg - erythromycins

États-Unis - anglais - NLM (National Library of Medicine)

exela pharma sciences, llc - erythromycin lactobionate (unii: 33h58i7glq) (erythromycin - unii:63937kv33d) - erythromycin lactobionate for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information.) lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus

États-Unis - anglais - NLM (National Library of Medicine)

nexus pharmaceuticals inc. - erythromycin lactobionate (unii: 33h58i7glq) (erythromycin - unii:63937kv33d) - erythromycin lactobionate for injection, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta-hemolytic streptococci); streptococcus pneumoniae (diplococcus

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - erythromycin stearate - oral tablet - 250mg